BRIM Biotechnology focuses on developing innovative treatments through its proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) platform. This platform is designed to address various therapeutic areas, leveraging the multifunctional properties of PDSP, which include anti-angiogenic, anti-tumorigenic, and neurotrophic effects. The company has secured a worldwide license for PDSP, enabling it to explore a range of applications, including treatments for dry eye disease, corneal wound healing, diabetic ulcers, osteoarthritis, and muscle/tendon regeneration. BRIM's lead asset, BRM421, is currently in Phase 3 clinical trials for dry eye disease, demonstrating promising safety and efficacy in prior studies.

In addition to BRM421, BRIM is advancing other candidates such as BRM424 for neurotrophic keratitis and BRM521 for osteoarthritis. The PDSP platform's unique mechanism of action promotes the proliferation and differentiation of limbal stem cells, facilitating corneal repair and cartilage regeneration. This innovative approach positions BRIM at the forefront of regenerative medicine, with the potential to significantly improve patient outcomes in ophthalmology and joint health. The company’s commitment to translational science and its robust pipeline reflect its dedication to addressing unmet medical needs in these critical areas.

Taiwan

BRIM is a clinical-stage company developing novel peptide treatments for hard-to-treat diseases. BRIM’s first-in-class assets are based on its innovative stem cell regenerative PDSP technology platform, which has the potential to be effective in multiple therapy areas and indications.  

BRIM Biotechnology

Company Details